Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18983992 | 0.86 | HCAR2 (0.59) | HCAR2LMNAABCG2SMN1; SMN2MAPT | |
| SCHEMBL28375604 | 0.81 | LMNA (0.61) | HCAR2LMNAABCG2SMN1; SMN2MAPT | |
| SCHEMBL6937665 | 0.81 | SMN1; SMN2 (0.58) | HCAR2LMNAABCG2SMN1; SMN2MAPT | |
| SCHEMBL30266517 | 0.81 | LMNA (0.61) | HCAR2LMNAABCG2SMN1; SMN2MAPT | |
| SCHEMBL6937661 | 0.81 | SMN1; SMN2 (0.58) | HCAR2LMNAABCG2SMN1; SMN2MAPT | |
| SCHEMBL369705 | 0.79 | HCAR2 (0.69) | HCAR2LMNAABCG2SMN1; SMN2MAPT | |
| SCHEMBL1862223 | 0.79 | HCAR2 (0.69) | HCAR2LMNAABCG2SMN1; SMN2MAPT | |
| SCHEMBL5598744 | 0.79 | HCAR2 (0.74) | HCAR2LMNAABCG2SMN1; SMN2MAPT | |
| SCHEMBL5598741 | 0.79 | HCAR2 (0.74) | HCAR2LMNAABCG2SMN1; SMN2MAPT | |
| SCHEMBL26653747 | 0.78 | HCAR2 (0.57) | HCAR2LMNAABCG2SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818584-B | Method for synthesizing alpha, beta-unsaturated amide compound by visible light catalysis | 闽南师范大学 | 2023-05-09 | — | — | CN | disclosed |
| CN-108884047-B | Intermediates for the synthesis of aryl or heteroaryl substituted 5-hydroxy-1, 7-naphthyridine compounds and methods for their preparation | 沈阳三生制药有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| CN-111018735-B | Preparation method of cinnamamide compound | 河南农业大学 | 2021-09-07 | — | — | CN | disclosed |
| EP-3287456-B1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| CN-111018735-A | Preparation method of cinnamamide | 河南农业大学 | 2020-04-17 | — | — | CN | disclosed |
| CN-110818584-A | Method for synthesizing α -unsaturated amide compound by visible light catalysis | 闽南师范大学 | 2020-02-21 | — | — | CN | disclosed |
| US-9994566-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-06-12 | — | — | US | disclosed |
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
| EP-3287456-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| EP-1630165-B1 | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20080045547-A1 | Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use | DOV PHARMACEUTICAL, INC. | 2008-02-21 | — | — | US | disclosed |
| EP-1648896-B1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES | FERRER INT (ES) | 2008-02-13 | — | — | EP | disclosed |
| US-20070129383-A1 | Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | FERRER INTERNACIONAL S.A. (ES) | 2007-02-22 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1674454-A1 | SUBSTITUTED 2-AMINO- 1,2,4 TRIAZOLO 1,5-a PYRIMIDINE DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-06-28 | — | — | EP | disclosed |
| EP-1630165-A1 | [1,2,4 ]TRIAZOLO [1,5-A]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | HCAR2 2695/4885LMNA 4876/4885ABCG2 604/4885 |
| US-20080045547-A1 | Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use | PNPO, INPP5A, P2RY6 | HCAR2 3909/4885LMNA 4207/4885ABCG2 27/4885 |
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | GABRB1, GABRA1, GABRB2 | HCAR2 139/4885LMNA 2305/4885ABCG2 493/4885 |
| US-20070129383-A1 | Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof | ADORA1, ADORA2B, ADORA3 | HCAR2 1041/4885LMNA 3684/4885ABCG2 50/4885 |
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HIF1AN, EGLN3, EGLN2 | HCAR2 400/4885LMNA 2841/4885ABCG2 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.